It is with great pleasure that we can announce, that Dr. Roger Frechette has accepted the position as the new MVA-ambassador on the east coast, where he will replace Torsten Jepsen, who has chosen to return to Denmark.It is not an easy task to follow in Torsten Jepsens footprints, as he has a done a tremendous effort in branding Medicon Valley in one of the world’s most important biotech clusters – an effort which among other things resulted in the partnership agreement between the US State of Massachusetts and the Medicon Valley Regions.
“With Dr. Roger Frechette as our new ambassador in Boston, we have nevertheless succeeded in recruiting a person perfectly suited for the task. With his experience, network and in-depth knowledge of life science, I am confident that we will continue to be uniquely positioned to brand Medicon Valley and serve the interest of our MVA-members in one of the most vibrant life science environments in the world” says Peter Nordström, Executive Vice President, Head of MVA Ambassador Program
“I am delighted to be working with MVA as the newest member of the Life Sciences Ambassador Program. Medicon Valley is a bright light on the international Life Sciences landscape and I am looking forward to playing a role in the region’s growth while connecting organizations in Medicon Valley with the Boston/Cambridge cluster and beyond.” Roger Frechette says in a comment from Boston
About Dr. Roger Frechette
Dr. Frechette is Co-Founder and Principal of New England PharmAssociates, a consultancy offering on-demand executive and advisory services to life sciences enterprises. He is a Co-Founder and Adviser of Frontiera Therapeutics, a startup developing therapeutics for vascular leak. He is also a volunteer adviser and mentor with several Boston area biotech incubators and startup mentoring programs. Previously, Dr. Frechette was Co-Founder of MaxThera, an antibacterial drug discovery company. MaxThera was sold in 2010 to Biota Holdings Limited, a Melbourne Australia anti-infectives company. Prior to starting MaxThera, Dr. Frechette was a drug discovery and life-sciences consultant following his role as Project Director at Paratek Pharmaceuticals (Boston). At Paratek he led the team that discovered PTK0796 (currently in Phase III clinical trials) with strategic partner Glaxo-Wellcome, and the pre-clinical development program that was carried out with a multinational team of consultants and contractors. Previously, he was Associate Director of Chemistry at RiboGene (Hayward, CA), where he built the chemistry department and managed two drug discovery programs in collaboration with strategic partner Dainippon Pharmaceuticals. He began his career as a medicinal chemist at the R.W. Johnson Pharmaceutical Research Institute (J&J, Raritan, NJ).
Dr. Frechette was a Post-Doctoral Fellow at Yale University, earned his PhD in Organic Chemistry from Wesleyan University and his BA in Chemistry from College of the Holy Cross.
Dr. Roger Frechettes LinkedIn profil can be found here
[shareaholic app="share_buttons" id="15743046"]